BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25966226)

  • 21. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
    Terp SK; Stoico MP; Dybkær K; Pedersen IS
    Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a multiplex MethyLight assay for the detection of DAPK1 and SOX1 methylation in epithelial ovarian cancer in a north Indian population.
    Kaur M; Singh A; Singh K; Gupta S; Sachan M
    Genes Genet Syst; 2016 Nov; 91(3):175-181. PubMed ID: 27452040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Methylation of selected tumor-supressor genes in benign and malignant ovarian tumors].
    Cul'bová M; Lasabová Z; Stanclová A; Tilandyová P; Zúbor P; Fiolka R; Danko J; Visnovský J
    Ceska Gynekol; 2011 Sep; 76(4):274-9. PubMed ID: 22026068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer.
    Chmelarova M; Dvorakova E; Spacek J; Laco J; Palicka V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):294-7. PubMed ID: 24145767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
    Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
    McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H
    Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of circulating methylated opioid binding protein/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma.
    Zhou F; Ma M; Tao G; Chen X; Xie W; Wang Y; Cao X
    Clin Lab; 2014; 60(5):759-65. PubMed ID: 24839818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.
    Wasenang W; Chaiyarit P; Proungvitaya S; Limpaiboon T
    Clin Epigenetics; 2019 Mar; 11(1):39. PubMed ID: 30832707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
    Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
    Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
    Zhu X; Yang H; Lang J; Zhang Y
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
    Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
    Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
    Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
    Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
    Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
    Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
    Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
    Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection.
    Zhou F; Cao X; Liu M; Wang Y; Tao G
    Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer.
    Chung VY; Tan TZ; Huang RL; Lai HC; Huang RY
    Gene; 2017 Nov; 635():9-15. PubMed ID: 28887161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
    Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
    Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.